

IN THE CLAIMS

1-83 (withdrawn).

84. (currently amended) A transdermal delivery system consisting essentially of a blend of:

(a) one or more hydrophobic acrylic polymers; and

(b) a therapeutically effective amount of one or more drugs, at least one of which is of low molecular weight and liquid at or about room temperatures,

wherein said system is substantially free of both water and liquids having a normal boiling point (i) below processing temperatures and (ii) equal to or greater than the normal boiling points of the low molecular weight drugs.

85. (canceled).

86. (currently amended) The transdermal delivery system of claim 84 wherein said acrylic-based polymers include a C<sub>4</sub>-C<sub>12</sub> alkyl acrylate.

87. (currently amended) The transdermal delivery system of claim 86 wherein said acrylic-based polymers include a C<sub>1</sub>-C<sub>4</sub> alkyl acrylate hardening monomer.

88. (currently amended) The transdermal delivery system of claim 87 wherein said acrylic-based polymers include a functionalizing monomer.

89. (currently amended) The transdermal delivery system of claim 88 wherein said acrylic-based polymers include a cross-linking agent.

90. (previously added) The transdermal delivery system of claim 84 wherein said at least one of said one or more drugs has a molecular weight of less than about 300 MW.

91. (previously added) The transdermal delivery system of claim 84 including from about 3% to 35% of said therapeutically effective amount of one or more drugs.

92. (currently amended) A transdermal delivery system consisting essentially of a blend of:

- Any*
- (a) ~~an~~ a hydrophobic acrylic-based polymer; and
  - (b) a therapeutically effective amount of a drug having a low molecular weight and being a liquid at or about room temperatures, wherein said system is substantially free of both water and liquids having a normal boiling point
    - (i) below processing temperature and
    - (ii) equal to or greater than the normal boiling points of the low molecular weight drugs,

whereby said transdermal drug delivery system, subsequent to processing, is free of said ~~solvents~~ water and liquids.